Drug Profile
Research programme: anticancer gene-based drug targeting technology - Trizell
Alternative Names: ScavidinLatest Information Update: 16 Sep 2010
Price :
$50
*
At a glance
- Originator Ark Therapeutics
- Class Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Sep 2010 Discontinued - Preclinical for Cancer in Finland (IV)
- 17 May 2010 Preclinical development is ongoing in Finland
- 11 Mar 2008 This programme is still in active development